43 Thorndike Street
Cambridge, MA 02141
United States
617 682 0917
https://amylyx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 384
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Joshua B. Cohen | Co-Founder, Co-CEO & Director | 1,08M | 672,61k | 1992 |
Mr. Justin B. Klee | Co-Founder, Co-CEO & Director | 1,08M | S.O. | 1991 |
Mr. James M. Frates M.B.A. | Chief Financial Officer | 763,16k | 1,73M | 1967 |
Ms. Gina M. Mazzariello | Chief Legal Officer & General Counsel | 689,26k | S.O. | 1971 |
Dr. Camille L. Bedrosian M.D. | Chief Medical Officer | 232,6k | S.O. | 1953 |
Mr. Tom Holmes | Chief Technical Operations Officer | S.O. | S.O. | S.O. |
Lindsey Allen | Head of Investor Relations & Communications | S.O. | S.O. | S.O. |
Ms. Shauna Horvath | Head of Global Marketing | S.O. | S.O. | S.O. |
Ms. Linda A. Arsenault | Chief Human Resources Officer | S.O. | S.O. | S.O. |
Mr. Chris Aiello | Head of Canada & GM | S.O. | S.O. | S.O. |
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
L’ISS Governance QualityScore de Amylyx Pharmaceuticals, Inc. en date du 29 juin 2024 est 8. Les scores principaux sont Audit : 8; Société : 6; Droits des actionnaires : 8; Compensation : 9.